Alia Rashid

Alia Rashid has an extensive work experience in the field of clinical development and healthcare. Alia is currently working as the Vice President of Clinical Development at Ascidian Therapeutics since March 2023. Prior to this, they held the position of Senior Director of Clinical Development Lead Ophthalmology at Editas Medicine from November 2021 to April 2023.

Between July 2017 and December 2021, Alia served as the Senior Medical Director of Clinical Development at Gemini Therapeutics. Before that, they were the CEO/Founder of Blue Owl Ventures from January 2017 to June 2017, where they focused on investing in healthcare, biotechnology, and green futures.

Alia also worked as a Medical Director at Annexon Biosciences from May 2016 to November 2016. Here, they were involved in the clinical development of classical complement pathway inhibitors for the treatment of neurodegenerative diseases. Alia gained further experience as a Medical Director at Avalanche Biotechnologies, Inc. from April 2015 to December 2015.

Before transitioning into the industry, Alia pursued opportunities in academia and research. Alia was a Media participant at Exponential Medicine @ Singularity University from November 2014 to December 2015. Alia also served as a Clinical Development Physician at Genentech from July 2014 to May 2015.

Alia had specialized training and fellowships at renowned institutions such as the Massachusetts Eye & Ear Infirmary, Harvard Medical School, and Emory University School of Medicine. At the former, they worked as an Ophthalmic Pathology Fellow from July 2013 to July 2014. At the latter, they held the position of Ophthalmic Oncology & Pathology Fellow from May 2011 to June 2013.

Alia Rashid attended the University of Birmingham Medical School from 2000 to 2005, where they obtained their MBChB degree in Medicine. In July 2005, they obtained their M.D. (MBChB) certification.